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Abstract
Purpose of Review This review uses clinical cases to highlight some of the ethical dilemmas currently faced by oncologists,
geneticists and others who request genetic testing for inherited cancer disorders.
Recent Findings Recent ethical guidance supports clinicians in testing patients when other family members decline similar
testing, even when such testing will reveal those family members’ genetic status. And increasingly there is acknowledgement
that when a patient declines to share genetic results with family members, clinicians may have an ethical duty to breach patient
confidentiality in order to inform at-risk relatives to whom theymay owe a duty of care, so that they can choose to access genetic
testing and potentially life-saving screening and treatment.
Summary Genetic testing for inherited cancer disorders raises multiple ethical issues, which cannot always be easily resolved by
discussion with patients, or with their family members. Clinical ethics committees can provide valuable assistance in resolving
the dilemmas presented in these cases.
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Introduction
Diagnostic genetic testing is often undertaken around the time
that a patient has received a life-changing cancer diagnosis
and is undergoing treatment. It may also be the first time that
an inherited cancer predisposition has been suspected in the
family; and the possibility of such a disposition clearly has
profound potential implications for other family members,
which may include adults and children, and both near and
more distant relatives. The greater availability of screening
for early detection of cancer has increased the importance of
relatives being made aware of inherited cancer predisposition
syndrome diagnoses, so that they can access appropriate med-
ical services. Hence, genetic testing of relatives for inherited
cancer syndromes is a frequent topic of ethical discussion in
both genetics departments and clinical ethics committees.
At present, it is generally considered to be the responsibility
of the patient to disseminate their relevant genetic information
appropriately to their relatives [1••]. Clinicians may, and usually
do, help to facilitate this by providing patients with a letter or
leaflet to pass to relevant family members. However, there is no
formal procedure in place for ascertaining whether this has
happened; or for determining what to do if it becomes clear that
it has not. Also, several studies have found patients do not
always inform family members of their risk, with barriers to
disseminating this information including a desire to protect
oneself and/or family from potentially distressing information,
lack of contact or closeness with relatives and/or poor under-
standing of the risks posed and its relevance to others [2, 3, 4•].
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Most families do understand the importance of sharing
their genetic information with relatives, and outright refusal
to inform relatives is rare. However, in our practice in the
South West Thames Regional Genetics Service at St
George’s Hospital, London, we have encountered cases over
a number of years where disclosure has been refused. Our
policy then is to discuss the case in the departmental meeting
in the first instance, and then to take the case to the hospital
clinical ethics committee (CEC) if a consensus cannot be
reached. We also take to the CEC cases where we are consid-
ering contravening the wishes of the patient. Finally, there is
also available a national forum in the UK, called Genethics,
available for discussing ethically challenging cases
(genethicsforum.ning.com).
Here we discuss two of our recent ethically difficult cases,
with a view to highlighting some of the major ethical issues
that can arise concerning the diagnosis and disclosure of
inherited cancer predisposition syndromes. Some details of
the cases, including names, have been changed so as to protect
patient confidentiality.
Cases
Case 1—BRCA2 Predictive Testing in an Identical Twin
and Disclosure of Genetic Test Results
Within a Family: the Right to Know, and the Right Not
to Know
Background
Clara was a patient known to Clinical Genetics who had not
been seen for many years. She requested another appointment
at the age of 38 years, attended with her husband and was seen
by a genetic counsellor. Clara had been aware for some time
that a BRCA2 gene pathogenic variant was present in her fam-
ily. Female carriers of such variants have up to 85% lifetime risk
(up to age 80) of breast cancer compared with 12% population
risk, and up to ~ 30% risk of ovarian/fallopian tube cancer
compared with ~ 2% in the population. The variant was first
identified in Clara’s mother, who had breast cancer aged
39 years and died from ovarian cancer, which was diagnosed
when she was aged 47 years. Clara’s older sister had undergone
predictive genetic testing, been found to carry the variant, and
chose to pursue risk-reducing mastectomy and salpingo-oopho-
rectomy. Clara had declined testing when she was seen in the
genetics service previously, but was now starting to think about
risk-reducing surgery, since she had completed her family and
was approaching the age at which this is recommended. Clara
said that her identical twin sister, Sarah, had also previously
declined predictive testing some years ago and, unlike Clara,
was still adamant that she did not wish to be tested. Both twins
were receiving high-risk breast screening, with annual breast
MRI (magnetic resonance imaging), which would not be indi-
cated in the absence of carrying the familial BRCA2 pathogenic
variant. Risks of unnecessary breast screening include increased
anxiety and the potential for false positive results, leading to
further investigation. There is no recommended surveillance for
ovarian cancer, and risk-reducing bilateral salpingo-
oophorectomy would not be recommended for an individual
at 50% risk. Following the genetic counselling session, Clara
was keen to have predictive genetic testing, but explicitly stated
that she would not inform Sarah about her result. The sisters
had a close relationship, although they were living in different
countries.
Ethical Questions Raised by Case 1
& How would Clara’s result inform Sarah’s risks?
& Does the choice by Sarah not to be tested preclude Clara
from having the right to be tested?
& Do patients’ relatives have a right to be made aware of
genetic information from which they could benefit?
& Can the duty of confidentiality be breached in order to
inform them, on the basis that they are owed a duty of care
by the clinician?
& In what circumstances might healthcare professionals be
able ethically to breach confidentiality?
Principles of Medical Ethics as a Framework for Consideration
of the Issues in Case 11
Beneficence
& Clara could potentially avoid physical harm to herself, if
she was shown to carry the gene pathogenic variant, by
The Clinical Ethics Committee at St George’s Hospital, London, is a
multidisciplinary committee sponsored by the Trust and the University
comprising doctors, nurses, allied health professionals, two health care
students, and lay individuals who meet monthly, or urgently, to
consider ethically complex cases arising in the hospital. Clinicians
present cases to the committee, and members debate the ethical issues
before potentially making a non-binding recommendation to the pre-
senting clinicians about how to proceed. The minutes of the ethics
committee meeting are usually placed into the patient’s medical record,
if so decided by the referring clinicians (albeit if they are not, then they
are still legally discoverable), and have been used to support the actions
of clinicians in the event of complaints or litigation, or can be used by
litigants in actions against the hospital. Clinicians report often finding
the ethics committee discussions and recommendations useful in
informing decision-making and explaining these decisions to patients,
families and other clinical teams.
1 A very commonly used ‘model’ for analysing ethically difficult dilemmas,
offered in Beauchamp TL and Childress FL (2013) Principles of Biomedical
Ethics, Seventh Edition, Oxford University Press, Oxford. There are, of
course, other approaches to clinical ethical problem solving; for example,
those in the ‘utilitarian’, rather than ‘principled’, tradition.
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putting in place measures to reduce her cancer risk (such
as risk-reducing bilateral salpingo-oophorectomy)
& She could avoid the mental distress that would arise from
continued uncertainty concerning her genetic status
Non-maleficence
& Non-disclosure of Clara’s genetic test result to Sarah
could result in her undergoing unnecessary breast
screening (if the BRCA2 pathogenic variant were
shown not to be present), or not pursuing risk-
reducing surgery (if the variant were shown to be
present). Hence, non-disclosure of the test results
on Clara could cause harm to Sarah.
Justice and Autonomy
& Patients have a right to access testing for themselves, so
that Clara has a right to be tested.
& Relatives such as Sarah should not be ‘forced’ to know, or
given without their consent, genetic test results relevant to
them
Consultation with Clinical Ethics Committee Following dis-
cussion in departmental meetings, the case was discussed at
a meeting of the hospital Clinical Ethics Committee2. There
was unanimous agreement that Clara should be offered pre-
dictive BRCA2 genetic testing. In that, it was concluded that
the potential personal medical benefit to Clara outweighed the
duty to avoid her sister inadvertently becoming aware of the
result. Also, although the sisters had grown up believing they
were identical twins, they had not undergone zygosity testing,
and so there was a small chance that they were non-identical.
Finally, once Clara had undergone genetic testing, it would
still be recommended that Sarah undertake independent test-
ing to confirm her own result, which could be pursued inde-
pendent of Clara being tested, or independent of the results of
such testing.
The outcome of the case was that Clara proceeded with
genetic testing, whilst respecting Sarah’s autonomy and
choice not to pursue testing.
Case 2—Lynch Syndrome Investigations
and Non-disclosure of Results to Relatives
Background
Joan (57) was diagnosed with endometrial cancer at 56 years
and was referred to the clinical genetics service by her
oncologist in order to discuss her personal and family history
of cancer.
Joan attended the appointment alone and was seen by a
genetic counsellor. She had undergone a total hysterectomy
and bilateral salpingo-oophorectomy, and was nearing the end
of her radiotherapy treatment. During the genetic counselling
appointment, she was informed that her personal and family
history of cancer might be suggestive of a hereditary cancer
predisposition condition called Lynch syndrome. It was noted
that Joan’s sister had been diagnosed with colorectal cancer at
48 years and her mother had been diagnosed with renal cancer
(histology unknown) at 41 years.
Lynch syndrome is an inherited cancer predisposition syn-
drome associated with a pathogenic variant in MLH1,MSH2,
MSH6 or PMS2. Cancer risks vary according to the gene, but
risks for certain cancers are significantly higher than the gen-
eral population risk. This can be as high as 75% lifetime risk
of bowel cancer in males, with up to a 55% lifetime risk of
bowel cancer in females and 40% lifetime risk of endometrial
cancer. The syndrome is also associated with gastric, ovarian
and renal pelvis cancer, as well as several other cancers to a
lesser extent. Screening recommendations include 2-yearly
colonoscopies from 25 years of age, as regular bowel screen-
ing can significantly reduce the risk of developing bowel can-
cer. Risk-reducing hysterectomy and bilateral salpingo-
oophorectomy are recommended for female Lynch carriers
from the age of 40 years, although this is dependent upon
which gene is involved in the family. Individuals with a path-
ogenic variant associated with Lynch syndrome have a 50%
chance of passing the variant on to a child.
Tumours caused by Lynch syndrome tend to show certain
characteristics, and Lynch syndrome testing is often initially
performed by looking for protein markers within the tumour,
using immunohistochemistry of the mismatch repair proteins
(MMR-IHC). These proteins are called MLH1, MSH2,
MSH6 and PMS2. If one or more proteins is/are missing, it
is possible that the cancer diagnosis is attributable to Lynch
syndrome.
Joan consented to undergo genetic investigation of her
stored endometrial cancer sample. The results demonstrated
an abnormal staining pattern (loss of expression of the MSH2
and MSH6 proteins), suggestive of Lynch syndrome.
The genetic counsellor wrote to Joan with the results, plus
information about the next steps, which included arranging
germline testing for the MSH2 and MSH6 genes in order to
determine whether the loss of protein expression was caused
by a pathogenic variant in one of the genes, causing Lynch syn-
drome. When the genetic counsellor called Joan a few weeks
later to follow up on the letter, Joan informed her that she had
not opened her results letter and was not planning to do so in the
near future. In subsequent phone calls, Joan declined any further
genetic counselling appointments, and also declined a referral for
colonoscopy. She also said that she would not share any of the
2 The Committee offers ‘facilitation’ of ethical consideration of cases, rather
than either prescribing or proscribing particular ethical decisions.
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information she had been given with her family. Her oncologist
and surgeon also then raised concerns about a possible diagnosis
of Lynch syndrome in Joan, as well as the risk to her relatives, but
Joan again declined to engage in further discussion.
Ethical Issues Raised by Case 2
& Should we respect Joan’s privacy and right to
confidentiality?
& Do we have a duty to inform Joan’s relatives of their
potential genetic risk?
Principles of Medical Ethics as a Framework for Consideration
of Issues in Case 2
Beneficence
& Non-disclosure may serve to sustain the clinician-patient
relationship, which has value in itself
& Sustaining the relationship would offer some hope that
Joan may later change her mind and agree to be tested,
to her benefit and potentially to the benefit of her relatives
& Awareness now of the currently known genetic informa-
tion would allow any relative of Joan’s to decide to access
tests, screening or treatment, to their benefit.
Non-maleficence
& Breaching confidentiality may cause mental distress to
Joan, and so should be avoided.
Autonomy
& Any patient has the right to control dissemination of their
medical, including genetic information
Justice
& All genetic information is inherently familial. Joan’s
refusal of further testing, and of disclosure of her cur-
rent genetic information to her relatives, deprives those
relatives of the opportunity to make choices about their
own healthcare. That is, Joan’s decision deprives her
relatives of the opportunity of choice that she has taken
for herself; so that they will remain unaware of their
potential risks. Hence, Joan and her relatives are not
being treated similarly and therefore ‘fairly’ by way
of Joan’s decisions.
Consultation with Clinical Ethics Committee Following dis-
cussion within departmental meetings, this case was discussed
at a meeting of the hospital Clinical Ethics Committee. The
CEC supported the genetics service speaking to other mem-
bers of Joan’s medical team in order to encourage her to un-
dergo germline testing and to disclose the information to her
relatives. It was further determined that, if she continued to
refuse testing and disclosure, a letter should be sent to her sons
inviting them to contact their local genetics service if they
would like to discuss the known family history of cancer, that
is falling short of disclosure of any genetic information
concerning Joan.
At the time of writing, the case is still ongoing.
Discussion
Whilst quite different in their detail genetically and clinically,
both of these cases address the fact that genetic information is,
by definition, shared, at least in part, by multiple family
members.
The right of patients to undergo predictive genetic testing,
even when this may reveal information about other family
members who may not wish to have testing, is an established
one, albeit this has not always been the case [5]. However, the
accepted ethical convention is for the geneticist or genetic
counsellor to discuss the implications of this with the proband
or patient, and in many cases, this proves to be accepted.
Testing of the intervening relative (person in the family tree
in between the relative who is known to carry the pathogenic
gene variant and the person presenting) has advantages of
avoiding inadvertent disclosure of carrier status by revealing
that a relative is an obligate carrier; it refines the risk for the
original patient and may avoid the need for testing if the in-
tervening relative tests negative. However, this approach is
not possible in all cases.
The ethical implications are particularly challenging when
dealing with identical twins since, by definition, the testing of
one twin reveals the status of the other. However, even if
neither twin undergoes testing, if one develops the familial
disease under consideration, the risks to the other are likely
to be clarified in any event. Albeit there is always the possi-
bility, especially in the case of commoner cancers such as
breast cancer, that the diagnosis might be coincidental. A case
of twin testing was reported in South Africa, where zygosity
testing was suggested to clarify the probability of the twins
being identical before a predictive test for Huntington disease
[6]. However, the twin who did not wish to be tested declined
zygosity testing and predictive testing went ahead for the other
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twin despite concerns being raised by the team looking after
the twin who did not wish to be tested.
Ethical issues are often discussed using the four pillars
mentioned above, that is ‘autonomy’, ‘beneficence’ and
‘non-maleficence’ and ‘justice’. However, when considering
the rights of more than one individual to be tested, or not,
clearly these pillars may stand in direct opposition to one
another.
The principle of autonomy would infer that Clara has the
right to be tested, and that Sarah has the right not to be tested.
The principle of beneficence suggests that testing Clara is the
right course, but that not forcing, or risking disclosure to Sarah
of Clara’s test results is also right. Non-maleficence in Sarah’s
case would infer avoiding risking the trauma of learning an
unwanted test result, whereas in Clara’s case it would infer
allowing her to control this aspect of her life and medical
treatment. So that, no matter which course is chosen, it will
inevitably prioritise the rights of one twin over those of the
other.
Some of these conflicts of ethical principle can be avoided
if the family member who would wish to decline testing re-
mains unaware of the result. However, there are significant
practical problems in maintaining this, particularly if family
members are emotionally or geographically close. In Clara’s
case, even if Clara did not inform Sarah of her result, it is
likely that Sarah might become aware of it, should Clara be
found to have the pathogenic variant and choose to proceed
along the route of prophylactic surgery.
The second case also raises issues of information sharing
amongst families. In this case, however, the at-risk family
members are unaware of the risk in play and cannot be
consulted as to their opinions (without disclosure occurring).
In addition, the causative mutation has not been identified in
the proband, which may limit the ability to offer genetic test-
ing to other family members in the event that they were to
become aware of the risks. Furthermore, although unlikely in
the context of the family history, it is also possible that the loss
of MSH2 and MSH6 has occurred as an acquired (somatic)
event rather than inherited, and that other family members are
not at risk.
Discussions about information-sharing form an essential
part of the clinical genetics consultation and, in general, fam-
ily members are happy to inform family members of any
emergent risk. Indeed, gaining information for the benefit of
relatives is an important motivator for many people in seeking
genetic testing, although the process of informing the family
can then still be difficult [7, 8]. Despite this, there is evidence
that relevant information about genetic risk may well not be
passed on to family members, even when patients appear will-
ing to share it. And, in some cases, the significance of the
information may not be understood by family members even
when that information appears to have been passed on by the
proband [9].
The recent guidance from the Joint Committee for
Genomic Medicine states that, where consent to inform rela-
tives has been explicitly withheld, “it may be justified to break
confidence where the avoidance of harm by the disclosure
outweighs the patient’s claim to confidentiality” [1]. This will
involve weighing up the often competing ethical principles
discussed above. Respecting the patient’s right to confidenti-
ality may be consistent with the principles of beneficence,
non-maleficence and autonomy as far as the patient is con-
cerned, whereas failure to breach may result in harm to the
relative (contravening the principle of non-maleficence). It
may also deny the relative the right to potentially life-saving
medical treatment and the chance to make decisions about
their own health, breaching the principles of both beneficence
and autonomy.
The legal position in England andWales is perhaps unclear,
in terms of whether there can be not merely a potential right to
disclose genetic information about a patient or proband to a
‘third party’ but whether there might sometimes be a duty to
do so. Albeit there is a case ongoing in the English courts at
present that may clarify the position in that jurisdiction [10•],
which could, for example, be expressed in terms not of im-
posing ‘a duty to disclose’ but of a duty ‘reasonably to carry
out a balancing exercise’ in regard to the interests of the pa-
tient or proband and of the third party (for example in the
terms described above concerning the two cases presented).
Previous cases in the USA, including that of Pate v Threlkel,
have determined that it is sufficient for the doctor to tell the
proband to inform the relative [11]. However, the case of Safer
v Estate of Pack suggests that this may not always be suffi-
cient [12].
One concern that is frequently raised in discussion of such
cases is whether breaching the patient’s confidentiality will
irreparably damage the clinician-patient relationship.
Another is the practical difficulties involved in tracing rela-
tives, especially where the proband is unwilling to assist, and
in regard to determining what amounts to sufficient familial
‘proximity’ for a relative to be ‘in the frame’. A third is wheth-
er knowledge that confidentiality may be breached so as to
inform relatives of risks may act as a deterrent to people com-
ing forward for genetic testing in the first instance. What is
clear, perhaps, ethically is that the risks and benefits of any
proposed breach should be weighed up in advance, discussion
clearly documented, and the patient or proband informed of
the proposed course of action, so as to be given the opportu-
nity to assist in informing relatives before the breach is made if
that is the decision come to [13]. And here referral to a clinical
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ethics committee may both assist the process per se and dem-
onstrate that it has properly occurred.
Conclusion
Testing in cancer genetics is often complex in its clinical and
ethical implications, and very frequently raises inevitable is-
sues concerning other family members. So that explaining
those issues to the proband, or patient, is a very important
stage in the testing process. Clinicians not based in Clinical
Genetics services who identify complex cases with regard to
familial disclosure may wish to consider referral to a genetics
clinician for further discussion, before testing is undertaken. In
general, the refusal of a family member to access testing when
a pathogenic variant has been identified in the family is not a
sufficient reason to deny testing to other family members,
even if such testing results in disclosure of carrier status for
that individual. Refusal of a proband or patient to inform fam-
ily members of a relevant genetic result may justify the clini-
cian breaching patient confidentiality, but this should only be
undertaken after attempts have been made to persuade the
proband to disclose the information. Furthermore, the proband
should be informed of the planned disclosure in advance.
Whether law in England and Wales will develop towards, in
some circumstances, there being a duty to disclose remains to
be seen. The hospital clinical ethics committee, where avail-
able, may well be a valuable adjunct to decision-making, and
its deliberations may assist in explaining and supporting such
decisions.
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